论文部分内容阅读
蒽环类化合物普遍具有抗肿瘤活性,是临床上使用的一类广谱抗肿瘤抗生素,但有些化合物具有较大的毒性和耐药性,由此限制了该类化合物的进一步发展和应用,而采取对该类化合物的结构进行修饰和改造,是解决这些问题较为有效的途径。因此,人们通过全合成或半合成等各种方法,研究与开发新型蒽环类化合物药物,以期找到疗效更好的蒽环类抗肿瘤药物。笔者在结合自己的工作和参考国内外文献基础上,简要介绍蒽环类化合物的作用机制、耐药性和心脏毒性,主要综述蒽环类化合物A环、糖基以及孪药蒽环类化合物的构效关系,为将来新型蒽环类化合物研发提供参考。
Anthracycline compounds generally have anti-tumor activity and are a kind of broad-spectrum anti-tumor antibiotics used clinically. However, some compounds have greater toxicity and drug resistance, thus limiting the further development and application of these compounds. However, It is a more effective way to solve these problems to modify and modify the structure of these compounds. Therefore, people research and develop new anthracycline drugs through all-synthesis or semi-synthetic methods in order to find a better anthracycline antitumor drug. Based on our own work and reference of domestic and foreign literatures, the author briefly introduced the mechanism, drug resistance and cardiotoxicity of anthracyclines. The main contents of anthracyclines A, glycosyl and gemcitabine Structure-activity relationship for the future development of new anthracyclines provide a reference.